Thyroid surgeons are becoming increasingly more aware of a histologically distinct subset of thyroid carcinoma whose classificationfall s between well-differentiated and anaplastic carcinomas with respect to both cell differentiation and clinical behavior. This subtype oftumors has been categorized as poorly differen tiated or insular carcinoma, based on its characteristic cell groupings. Although the differentiation of insular carcinoma from other thyroid carcinomas has important prognostic and therapeutic significance, relatively little about insular carcinoma has been published in the otolaryngology literature. In this article, we describe a new case of insular carcinoma and we discuss the fin dings of our review of the literature. We conclude that insular thyroid carcinoma warrants aggressive management with total thyroidectomy foll owed by radioactive iodine ablation of any remaining thyroid tissue.
Introduction
In 1984, Carcangiu et al described a thyroid neoplasm whose characteri stics placed it between well-differentiated thyroid carcinoma and anaplastic thyro id carcinom a with respect to its morphologic, biologic, and clinical behavior. I They called this malignancy insular carcinoma based on its distinct microscopic features. These features include characteristic islands of neoplastic cells (insulae) that have indistinct nucleoli and that are surrounded by hypocellul ar fibrous tissue. Another characteristic commonly seen in insular carci noma is necrosis that creates islands of viable cells that surround small vessels and form a peritheliomatous pattem. !" Insular carcinoma has been shown to be thyroglobulin-positive and calcitonin-and carcinoembryonic-antigen-negative. 4 .5 Insular carcinoma also is considered to be identical to the "w uchemde Strum a" tumor described by Langh ans in 1907. 1 ,6This neoplasm has not been found to be rapidly or uniformly fatal, but it has a greater propensity for local and regional recurrence and distant metastatic behavior than do the well-diffe rentiated papillary and follicular carcinomas. v'-" Insular carcinoma has been consistent!y misdiagnosed. It has often been grouped with either solid or moderately differentiated tumors, and it has been mistaken for anaplastic carcinoma.!? Some authors have recommended that insular carcinom a be classified as a poorly differentiated thyroid tumor that is less aggressive than undifferentiated or anaplastic thyro id carcinoma, while others have suggested that insular carcinoma is an aggres sive variant of a well-differentiated thyroid cancer that manifests insular features .1, 2, 4, 9, 10 In several serie s,2,8.11 ,12authors reviewed archived pathologic specimens that fell into these categories and reclassified them as insular carcinomas based on the histol ogic crit eria established by Carcangiu et al. ' Yet even with this recl assification, we found only 260 cases that were previously reported in the literature. ':" Because of insular carcin oma' s aggressive nature , proper identification has important prognostic and therapeutic significance. In this article, we report a new case of insular carcinoma of the thyroid. We also discuss its behavior, diagnosis, and management, and we report the results of our review of the literature.
Case report
A 56-year-old black woman came to our center with a gradually enlarging neck mass, dysphagia, and dyspnea while lying flat. She reported no history of hoarseness, radiati on exposure, thyroid disease, or rapid growth of the mass. Physical examination revealed a markedly CLARINEX® (desloratadine)
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On immunohistochemical evaluation, the specimen was positive for thyroglobulin and negative for calcitonin, p53, and K167 . Electron microscopy detected features that were consistent with poorly differentiated carcinoma: epithelial cells with round nuclei, scattered chromatin, some secondary lysosomes, a dilated rough endoplasmic reticulum, and swollen mitochondria.
A thyroid scan and whole-body survey performed 6 weeks postoperatively detected an increased uptake in the right anterior neck. The patient was treated with 100 mCi of radioactive iodine ( 1311). A follow-up scan 1 week later showed that a small focus of tissue remained functional in the right anterior neck. The patient was maintained on thyroid hormone replacement therapy and external-beam radiation. Six years later, she exhibited no evidence of disease. However, she was later diagnosed with metastatic disease and was subsequently lost to follow-up. 
Results of previous studies
In our review of the literature, we identified 260 cases of insular carcinoma that were described with various degrees of detail in 29 reports.':" The findings discussed here are taken from one or more of these 29 reports .
Patients with insular carcinoma ranged in age from 11 to 86 years, and approximately two-thirds were female (ratio : 2.2 to 1). The most common initial signs were an enlarging neck mass or goiter; dysphagia and dyspnea were common in patients with large lesions. One patient had cervical spinal cord compression and biphasic stridor.!' Hoarseness was notably absent, although preoperative direct evaluation of vocal fold mobility was reported in only one case." Most patients were euthyroid, and only 7 of 60 (11.7%) had a history of radiation exposure to the neck. 1. 4, 14, 18, 28, 29 A small number of patients underwent scintigraphic examination to evaluate thyroid nodules. Radioactive thyroid scans detected a cold nodule in 18 of 23 patients (78.3%) and a hot nodule in 2 of 21 (9.5%).1,2.4,14,28 Reported rates of regional and distant metastasis present at the initial evaluation ranged from 5 to 52%; overall, metastatic disease was present in 94 of 248 patients (37.9%).1. 4,8,11.14,16.18,21,22,24,28,29 When the method of treatment was definitively reported, the most common treatment was total thyroidectomy, which was performed on 81 of 104 patients (77.9%)1, 2.4,8,13.14,17,22,28.29 ; 131 1ablation was performed on 72 of 110 patients (65.5%) who had undergone full or partial removal of their thyroid.1. 2 .4,5,8,13,14,17.22,28,29 Only five reports included data on cervical lymph node dissection; in these reports, 13 
Discussion
Insular carcinoma represents a distinct form of thyroid cancer whose clinical behavior falls in the spectrum between that of well-differentiated and anaplastic thyroid carcinoma.1.8,1 1,12 In our study , we noted a female preponderance, although Machens et al reported no significant 386 difference between the sexes on univariate analysis when insular carcinoma was compared with non insular carcinoma." The reported incidence of insular carcinoma in the literature ranges widely, from 0.4 to 10% of all thyroid cancers. 3 ,8,II,12,17,1 8
Histology. Insular carcinoma is characterized histologically by the presence of islands of neoplastic cells surrounded by hypocellular fibrous tissue. I Microscopic features common to both follicular and papillary carcinomas are found in insular carcinoma, which explains at least some ofthe confusion that attends to the diagnosis of these comparatively rare tumors .II Justin et al wrote that all insular carcinomas arise from follicular epithelium, and, indeed, most cases manifest a concomitant follicular pattern that can predominate the insular pattern.' Even so, the presence of ground-glass nuclei and findings on keratin staining that are characteristic of papillary carcinoma are not uncommon.' Necrosis is also a prominent finding, and both capsular and vascular invasion can be found within these turnors.P
The diagnosis of insular carcinoma ' is often elusive because these tumors have been classified as poorly differentiated papillary carcinomas when papillary features are present and as undifferentiated thyroid carcinomas of the small-cell category when papillary features are absent. I Insular carcinoma has also been confused with follicular carcinoma.':'! Pilotti et al demonstrated that insular carcinoma is a separate entity from widely invasive follicular carcinoma and is associated withsignificantly more advanced T and N stages." A multivariate analysis by Machens et al found no significant con-elation with extrathyroidal tumor extension or nodal metastasis." Tumors diagnosed as small-cell undifferentiated carcinomas with "compact" architecture were probably insular carcinomas.'?Many cases that were classified as undifferentiated have been shown to be lymphomas and medullary carcinomas .' -" Electron microscopy has been useful in distinguishing lymphomas from insular carcinomas because lymphomas do not have tight junctions or hemidesmosomal connections.i? Diagnosis of insular carcinoma by fine-needle aspiration biopsy has been reported .v :" A definitive diagnosis might not be feasible with cytologic smears, but fragments of tissue might reveal a characteristic trabecular pattern.' > Smears demonstrate high cellularity, microfollicle-like structures, low grades of atypia, irregular cohesive cell clusters, trabeculae with poorly outlined cytopl asm , nuclear inclusions and grooving, and cytoplasmic vacuoles that contain thyroglobulin. v-v -" The prominent single-cell pattern and atypia found on fineneedle aspiration biopsy suggests a lesion other than a papillary carcinoma; such a pattern and atypia can be differentiated from those seen in anaplastic lesions by the lack of spindle cells and a fewer number of atypical because insular carcinomas coexist with other thyroid carcinomas (e.g., papillary, follicular, and anaplastic), (2) because they share common cytologic features with microfollicular neoplasms, and (3) because they have no distinctive cytologic characteristics, cytodiagnosis of insular carcinomas by fine-needle aspiration biopsy can be complicated if a cell sample is obtained from a tumor component other than insular carcinoma.' They concluded that the only definitive way to diagnose thyroid insular carcinoma is by histologic examination of the excised tumor. Immunohistochemical staining of insular carcinomas for thyroglobulin has been uniformly positive.1,8.1?,1 8. 24 The absence of staining for calcitonin, surface and cytoplasm immunoglobulin, and leukocyte common antigen helps differentiate insular carcinomas from medullary carcinomas and malignant lymphomas (table)."> Geneticfactors. It has been reported that a mutation or deletion of the p53 gene is one of the most frequently detected genetic changes seen in human cancers in general, and this genetic alteration is important in thyroid carcinomas.P The p53 gene is frequently overexpressed in anaplastic carcinoma and uniformly absent in insular carcinoma." Additionally, mutations in the family of ras genes are found in a high percentage of insular carcinomas and widely invasive follicular carcinomas. 388 Prognosis. The prognostic significance of insular carcinoma is controversial, and some reports have been conflicting.v'? Papotti et al noted that patients whose tumors were 65 to 100% insular carcinoma experienced the same survival rates as did patients whose tumors were 24 to 45 % insular carcinoma, even though the former group had a significantly higher percentage of recurrences and distant metastases." Likewise, Ashfaq et al found that patients with predominantly insular carcinoma were as likely to be alive without evidence of disease as were patients whose tumors contained only a minor component of insular carc inoma.'? They added that tumors that had only a minor component of insular carcinoma were just as likely to exhibit regional and distant spread as were tumors that were predominantly insular carcinoma.
In their review of 63 cases, Ashfaq et al concluded that insular carcinoma within papillary or follicular carcinoma did not adversely affect the patient's prognosis and that the only significant factors that affect the behavior of insular thyroid carcinomas were advanced patient age and the tumor stage at diagnosis. Tumor stage at diagnosis has long been known to affect the prognosis of patients with well-differentiated thyroid carcinomas."
Conversely, other authors have found that insu lar carcinoma was associated with a worse prognosis than was well-differentiated carcinoma.":" One study found that even small amo unts of anap lastic dedifferentiation in a
